Literature DB >> 22067518

Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.

Alfonso Eirin1, Maria V Irazabal, Morie A Gertz, Angela Dispenzieri, Martha Q Lacy, Shaji Kumar, Sanjeev Sethi, Samih H Nasr, Lynn D Cornell, Mary E Fidler, Fernando C Fervenza, Nelson Leung.   

Abstract

In the kidney, immunoglobulin light chain amyloidosis (AL) can be deposited in vascular-limited AL (V-AL) or diffuse (D-AL) pattern. These patterns are associated with different clinical presentations. A nested case study was performed to describe these differences. V-AL was defined by the vascular-limited deposits. Cases were matched for age, sex and date of renal biopsy. There were 12 cases of V-AL (mean age 61 ± 11 years) and 24 cases of D-AL. Median follow-up was 26 months for V-AL and 38 months for D-AL, P = 0.14. Lambda was more common in D-AL (83.3%) than V-AL (50%, P = 0.04). Cardiac function was similar between the two groups. V-AL patients presented with lower renal function (serum creatinine = 2.1 versus 1.3 mg/dL, P = 0.02; estimated glomerular filtration rate 31 versus 59 mL/min/1.73m(2), P = 0.01 and creatinine clearance 38.5 versus 64 mL/min/1.73m(2), P = 0.02, respectively). Proteinuria was low grade in V-AL [0.4 (0.09-0.98) g/day] compared to nephrotic range in D-AL patients [8.0 (0.2-22) g/day, P < 0.001]. Stem cell transplantation was performed on 62.5% of the D-AL but on only 25% of the V-AL, P = 0.08. Median survival was longer in patients with D-AL (77.2 months) versus V-AL (40.6 months, log-rank P = 0.02). Our study found that V-AL patients presented with more severe renal insufficiency and less proteinuria than D-AL. There was a preference for λ light chain in the D-AL that was not noted in the V-AL. Patients with D-AL in this study had a longer median survival but most of them were stem cell transplantation candidates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22067518     DOI: 10.1093/ndt/gfr381

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  15 in total

Review 1.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

2.  A case of primary (AL) amyloidosis with predominantly vascular amyloid deposition in the kidney.

Authors:  Yoichi Murakami; Soken Hattori; Fumiko Sugiyama; Kazuyuki Yoshikawa; Takeshi Sugiura; Hideki Matsushima
Journal:  CEN Case Rep       Date:  2014-12-02

3.  Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the environment play a role?

Authors:  Ioannis Petrakis; Vasiliki Mavroeidi; Kostas Stylianou; George Efthymiou; Kostas Perakis; Eleftheria Vardaki; Spyridon Stratigis; Kostas Giannakakis; Kostas Kourouniotis; George Amoiridis; Andreas Plaitakis; Maria Joao Saraiva; Ken Ichi Yamamura; Eugene Daphnis
Journal:  Transgenic Res       Date:  2012-07-18       Impact factor: 2.788

4.  Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

Authors:  Nelson Leung; Morie Gertz; Robert A Kyle; Fernando C Fervenza; Maria V Irazabal; Alfonso Eirin; Shaji Kumar; Stephen S Cha; S Vincent Rajkumar; Martha Q Lacy; Steve R Zeldenrust; Francis K Buadi; Suzanne R Hayman; Samih H Nasr; Sanjeev Sethi; Marina Ramirez-Alvarado; Thomas E Witzig; Sandra M Herrmann; Angela Dispenzieri
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 8.237

5.  Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance.

Authors:  Mitchell H Rosner; Amaka Edeani; Motoko Yanagita; Ilya G Glezerman; Nelson Leung
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

6.  A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.

Authors:  Nelson Leung; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2016-03-18       Impact factor: 8.237

Review 7.  Amyloid nephropathy.

Authors:  Mazdak A Khalighi; W Dean Wallace; Miguel F Palma-Diaz
Journal:  Clin Kidney J       Date:  2014-03-13

8.  Bilateral kidney infarction due to primary Al amyloidosis: a first case report.

Authors:  Fabrice Mihout; Laure Joseph; Isabelle Brocheriou; Véronique Leblond; Shaïda Varnous; Pierre Ronco; Emmanuelle Plaisier
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

9.  Strategy and rationale for urine collection protocols employed in the NEPTUNE study.

Authors:  Marie C Hogan; John C Lieske; Chrysta C Lienczewski; Lisa L Nesbitt; Larysa T Wickman; Christina M Heyer; Peter C Harris; Christopher J Ward; Jamie L Sundsbak; Luca Manganelli; Wenjun Ju; Jeffrey B Kopp; Peter J Nelson; Sharon G Adler; Heather N Reich; Lawrence B Holzmann; Matthias Kretzler; Markus Bitzer
Journal:  BMC Nephrol       Date:  2015-11-17       Impact factor: 2.388

10.  Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.

Authors:  H Sugihara; D Chihara; K Seike; K Fukumoto; M Fujisawaa; Y Suehara; Y Nishida; M Takeuchi; K Matsue
Journal:  Blood Cancer J       Date:  2014-08-01       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.